Related Experiment Video
Updated: Jun 27, 2026

Determination of Tolerable Fatty Acids and Cholera Toxin Concentrations Using Human Intestinal Epithelial Cells and BALB/c Mouse Macrophages
Published on: May 30, 2013
Microencapsulation of cholic acid via complex coacervation enhances sustained release and antibacterial activity
Xiuling He1,2, Ganggang Qu1,2, Danqi Shen1,2
1Inner Mongolia Key Laboratory of Veterinary Fundamentals and Disease Prevention and Control for Herbivorous Livestock, Hohhot, China.
Abstract:
This study aimed to develop a microencapsulated cholic acid (CA) preparation to improve the stability, sustained-release performance, and antibacterial activity of CA for potential use in antibiotic-free animal production. CA microcapsules were prepared by complex coacervation using gelatin and gum arabic as wall materials, and the formulation was optimized by single-factor and orthogonal experimental designs. The optimal preparation conditions were a wall material concentration of 2.5%, a core-to-wall ratio of 1.8:1, and pH 4.1, yielding a drug loading rate of 49.73% and an encapsulation efficiency of 88.76%. The microcapsules showed spherical morphology, low hygroscopicity, improved thermal and storage stability, and a sustained-release profile over 72 h in simulated gastrointestinal media. Both free CA and microencapsulated CA significantly inhibited Escherichia coli growth (p < 0.001), while the microcapsules provided a more prolonged antibacterial effect consistent with controlled release. These findings indicate that complex coacervation is a practical strategy for improving CA performance and support the potential use of CA microcapsules as antimicrobial feed additives in livestock production.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Bioavailability Enhancement: Drug Permeability Enhancement
Oral Drug Delivery Systems: Delayed-Release Systems
Direct-Acting Cholinergic Agonists: Pharmacokinetics
iChip